Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. (2017)

Peer-Reviewed Study · Michelle De Witt; Alexander Gamble; Derek Hanson et al. · April 2017

Michelle De Witt et al., 2017-04: De Witt et al. compare mebendazole with vincristine for brain tumours, showing that the concentrations inhibiting GL261 viability, microtubule polymerisation and metaphase arrest are very similar.

In addition, using mebendazole as a seed for the National Cancer Institute (NCI) COMPARE program revealed that the top-scoring drugs were highly enriched in microtubule-targeting drugs.

Michelle De Witt et al., 2017-04: De Witt et al. compare mebendazole with vincristine for brain tumours, showing that the concentrations inhibiting GL261 viability, microtubule polymerisation and metaphase arrest are very similar. Study type: cell line work (GL261 glioblastoma) with NCI COMPARE analysis. N: not applicable. Country: USA (Feinstein Institute for Medical Research, Manhasset). Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: 'The authors declare they have no competing interests as defined by Molecular Medicine…'. Comparator: vincristine and the NCI COMPARE drug set.